A new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable...
The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Psychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD)...
Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
A group of doctors are urging researchers to look at psychedelics to ease the often overwhelming distress faced by women with late-stage gynaecological cancers.
Awakn Life Sciences has completed the sale of Awakn London Limited Ltd.,
With psilocybin showing promise for treating conditions such as depression and addiction, a team of scientists from the University of Southern Denmark has set out to...
Enosis Therapeutics, OVID Clinics and the MIND Foundation for Psychedelic Research have joined together to implement the world’s first in-clinic application of Virtual Reality (VR) combined...
In what has been described as a “historic trial”, ICEERS has suggested that the verdict of an ayahuasca trial in Mexico opens the door for the...
